Aurinia Pharmaceuticals Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutic drugs for the treatment of autoimmune diseases in Canada, the United States, China, and Switzerland. The company is developing voclosporin, a calcineurin inhibitor for the treatment of lupus nephritis, dry eye syndrome, and focal segmental glomerulosclerosis. It has a sales agreement with Cantor Fitzgerald & Co.; and a manufacturing collaboration and services agreement with Lonza Ltd. The company was formerly known as Isotechnika Pharma Inc. and changed its name to Aurinia Pharmaceuticals Inc. in October 2013. Aurinia Pharmaceuticals Inc. was founded in 1993 and is headquartered in Victoria, Canada.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:AUPH
CUSIPN/A
Phone250-708-4272
Debt
Debt-to-Equity RatioN/A
Current Ratio30.50
Quick Ratio30.50
Price-To-Earnings
Trailing P/E Ratio-6.32
Forward P/E Ratio-8.30
P/E GrowthN/A
Sales & Book Value
Annual Sales$420,000.00
Price / Sales1,168.64
Cash FlowN/A
Price / CashN/A
Book Value$1.97 per share
Price / Book2.95
Profitability
EPS (Most Recent Fiscal Year)($0.92)
Net Income$-70,790,000.00
Net Margins-8,193.08%
Return on Equity-20.67%
Return on Assets-17.74%
Miscellaneous
Employees33
Outstanding Shares84,480,000
Market Cap$490.82
Aurinia Pharmaceuticals (NASDAQ:AUPH) Frequently Asked Questions
What is Aurinia Pharmaceuticals' stock symbol?
Aurinia Pharmaceuticals trades on the NASDAQ under the ticker symbol "AUPH."
How were Aurinia Pharmaceuticals' earnings last quarter?
Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) released its earnings results on Thursday, May, 10th. The biotechnology company reported ($0.18) EPS for the quarter, missing analysts' consensus estimates of ($0.16) by $0.02. The biotechnology company earned $0.03 million during the quarter, compared to analysts' expectations of $0.05 million. Aurinia Pharmaceuticals had a negative return on equity of 20.67% and a negative net margin of 8,193.08%. View Aurinia Pharmaceuticals' Earnings History.
When is Aurinia Pharmaceuticals' next earnings date?
What price target have analysts set for AUPH?
6 equities research analysts have issued 1-year target prices for Aurinia Pharmaceuticals' stock. Their forecasts range from $9.00 to $16.00. On average, they expect Aurinia Pharmaceuticals' stock price to reach $12.1667 in the next year. This suggests a possible upside of 109.4% from the stock's current price. View Analyst Ratings for Aurinia Pharmaceuticals.
What is the consensus analysts' recommendation for Aurinia Pharmaceuticals?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aurinia Pharmaceuticals in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
What are Wall Street analysts saying about Aurinia Pharmaceuticals stock?
Here are some recent quotes from research analysts about Aurinia Pharmaceuticals stock:
- 1. According to Zacks Investment Research, "Aurinia Pharmaceuticals Inc. is a late stage biopharmaceutical company. It focuses on the development of therapeutic immunomodulating drug candidate. The company's lead drug includes Voclosporin for the treatment of lupus nephritis. Aurinia Pharmaceuticals Inc. is headquartered in Victoria, Canada. " (7/16/2018)
- 2. Cantor Fitzgerald analysts commented, "Aurinia reported 1Q18 financial results and provided an update on its corporate activities." (5/10/2018)
- 3. HC Wainwright analysts commented, "of FSGS and VOS Studies in 2Q18; Affirm Buy Stock Data 05/01/2018 Price $5.27 Exchange NASDAQ Price Target $12.00 52-Week High $8.19 52-Week Low $4.41 Enterprise Value (M) $239.5 Market Cap (M) $413 Public Market Float (M) 45.3 Shares Outstanding (M) 84.1 3 Month Avg Volume 606,874 Short Interest (M) 8.08 Balance Sheet Metrics Cash (M) $173.5 Total Debt (M) $0.0 Total Cash/Share $2.06 Book Value/Share $2.01 EPS Diluted Full Year – Dec 2016A 2017A 2018E 1Q (0.13) (0.92) (0.17) 2Q (0.10) (0.03) (0.21) 3Q (0.21) (0.16) (0.23) 4Q (0.21) (0.04) (0.24) FY (0.66) (0.92) (0.84) Revenue ($M) Full Year – Dec 2016A 2017A 2018E 1Q 0.1 0.0 0.0 2Q 0.1 0.3 0.0 3Q 0.0 0.0 0.0 4Q 0.0 0.0 0.0 FY 0.2 0.4 0.1 9 8 7 6 5 4 MAY-17 SEP-17 DEC-17 MAY-18 10 8 6 4 2 0 Vol. (mil) Price Phase 3 AURORA study progressing well and on track. The pivotal AURORA study evaluating voclosporin for the treatment of lupus nephritis (LN) remains on track to complete enrollment in 4Q18." (5/2/2018)
Who are some of Aurinia Pharmaceuticals' key competitors?
Some companies that are related to Aurinia Pharmaceuticals include Phibro Animal Health (PAHC), Insmed (INSM), Prestige Brands (PBH), PTC Therapeutics (PTCT), Cambrex (CBM), Mallinckrodt (MNK), AnaptysBio (ANAB), Aimmune Therapeutics (AIMT), Mirati Therapeutics (MRTX), G1 Therapeutics (GTHX), IMMURON Ltd/S (IMRN), ARMO Biosciences (ARMO), Pacira Pharmaceuticals (PCRX), Corcept Therapeutics (CORT) and Innoviva (INVA).
Who are Aurinia Pharmaceuticals' key executives?
Aurinia Pharmaceuticals' management team includes the folowing people:
- Dr. Richard M. Glickman, Founder, Chairman, Pres & CEO (Age 60)
- Mr. Michael R. Martin, Co-Founder & COO
- Mr. Dennis Bourgeault C.A., CFO & Sec.
- Mr. Robert B. Huizinga RN NNC, MSc(Epi), CNeph(C), Exec. VP of Corp. Devel.
- Dr. Neil Solomons M.D., Chief Medical Officer
Has Aurinia Pharmaceuticals been receiving favorable news coverage?
News stories about AUPH stock have trended somewhat positive this week, according to Accern. The research group rates the sentiment of press coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Aurinia Pharmaceuticals earned a news impact score of 0.12 on Accern's scale. They also gave news headlines about the biotechnology company an impact score of 47.50 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company's share price in the next several days.
Who are Aurinia Pharmaceuticals' major shareholders?
Which institutional investors are buying Aurinia Pharmaceuticals stock?
How do I buy shares of Aurinia Pharmaceuticals?
Shares of AUPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Aurinia Pharmaceuticals' stock price today?
One share of AUPH stock can currently be purchased for approximately $5.81.
How big of a company is Aurinia Pharmaceuticals?
Aurinia Pharmaceuticals has a market capitalization of $490.82 million and generates $420,000.00 in revenue each year. The biotechnology company earns $-70,790,000.00 in net income (profit) each year or ($0.92) on an earnings per share basis. Aurinia Pharmaceuticals employs 33 workers across the globe.
How can I contact Aurinia Pharmaceuticals?
Aurinia Pharmaceuticals' mailing address is 203-4464 MARKHAM STREET, VICTORIA A1, V8Z 7X8. The biotechnology company can be reached via phone at 250-708-4272 or via email at [email protected]
MarketBeat Community Rating for Aurinia Pharmaceuticals (NASDAQ AUPH)
MarketBeat's community ratings are surveys of what our community members think about Aurinia Pharmaceuticals and other stocks. Vote "Outperform" if you believe AUPH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AUPH will underperform the S&P 500 over the long term. You may vote once every thirty days.
